LLY - Eli Lilly and Company - Stock & Dividends

Eli Lilly and Company is a global pharmaceutical leader that discovers, develops, and markets innovative medicines to improve human health. The company's portfolio includes a range of treatments for diabetes, such as Basaglar, Humalog, and Jardiance, which help patients manage their blood sugar levels and reduce the risk of complications.

In addition to its diabetes franchise, Eli Lilly and Company has a strong presence in oncology, with products like Alimta, Cyramza, and Erbitux, which target various types of cancer. The company is also a leader in immunology, with medications like Olumiant, Taltz, and Cymbalta, which treat conditions such as rheumatoid arthritis, psoriasis, and depression.

Furthermore, Eli Lilly and Company offers a range of treatments for other diseases, including obesity, cardiovascular disease, and osteoporosis. Its product portfolio includes Zepbound, Cialis, and Forteo, which address specific patient needs in these areas. The company is committed to advancing its research and development efforts, with a focus on RNA and DNA-based therapies, as well as discovering new drug targets to create life-changing medicines.

To accelerate its innovation pipeline, Eli Lilly and Company has established strategic collaborations with other industry leaders, such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, and F. Hoffmann-La Roche Ltd. These partnerships enable the company to leverage its expertise and resources to develop new treatments for patients worldwide.

At the heart of Eli Lilly and Company's innovation efforts is the Lilly Seaport Innovation Center (LSC), a state-of-the-art research and development facility in Boston. This center is dedicated to advancing the company's efforts in RNA and DNA-based therapies, as well as discovering new drug targets to create life-changing medicines across several disease states.

With a rich history dating back to 1876, Eli Lilly and Company is headquartered in Indianapolis, Indiana, and continues to be a leader in the global pharmaceutical industry. The company's commitment to innovation, collaboration, and patient-centricity drives its mission to make life better for people around the world.